Document is current
Any future updates will be listed below
-
Authors
Sachpekidis, Christos https://orcid.org/0000-0001-8739-8741
Hajiyianni, Marina
Wennmann, Markus
Kopp-Schneider, Annette
John, Lukas
Sauer, Sandra
Dapunt, Ulrike
Weinhold, Niels
Menis, Ekaterina
Jauch, Anna
Bertsch, Uta
Hundemer, Michael
Brobeil, Alexander
Hillengass, Jens
Raab, Marc S.
Mai, Elias K.
Dimitrakopoulou-Strauss, Antonia
Goldschmidt, Hartmut
-
Funding
Funding for this research was provided by:
Deutsches Krebsforschungszentrum (DKFZ)
- License Information
-
More Information
Article History
Received: 20 April 2026
Accepted: 22 May 2026
First Online: 3 June 2026
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all participants enrolled in the study.
: Consent to publish has been received from all participants.
: There are no competing financial interests in relation to the work described. Christos Sachpekidis is an associate editor in this journal. Hartmut Goldschmidt declares the following: Grants and/or provision of Investigational Medicinal Product: Amgen, Array Biopharma/Pfizer, BMS/Celgene, Chugai, Dietmar-Hopp-Foundation, Janssen, Johns Hopkins University, Mundipharma GmbH, Sanofi. Research Support: Amgen, BMS, Celgene, GlycoMimetics Inc., GSK, Heidelberg Pharma, Hoffmann-La Roche, Karyopharm, Janssen, Incyte Corporation, Millenium Pharmaceuticals Inc., Molecular Partners, Merck Sharp and Dohme (MSD), MorphoSys AG, Pfizer, Sanofi, Takeda, Novartis. Advisory Boards: Adaptive Biotechnology, Amgen, BMS, Janssen, Sanofi, Honoraria / Nebentätigkeiten: Amgen, BMS, Chugai, GlaxoSmithKline (GSK), Janssen, Novartis, Sanofi, Pfizer. Support for attending meetings and/or travel: Amgen, BMS, GlaxoSmithKline (GSK), Janssen, Novartis, Sanofi, Pfizer. Elias K. Mai reports the following: Consulting or advisory role: Amgen, Bristol Myers Squibb/BMS, GlaxoSmithKline/GSK, Janssen-Cilag/J&J, Oncopeptides, Pfizer, Sanofi, Stemline and Takeda. Honoraria: Amgen, Bristol Myers Squibb/BMS, GlaxoSmithKline/GSK, Janssen-Cilag/J&J, Oncopeptides, Pfizer, Sanofi, Stemline and Takeda. Research funding: Bristol Myers Squibb/BMS, Janssen-Cilag/J&J, Sanofi and Takeda. Travel accommodations and expenses: Bristol Myers Squibb/BMS, GlaxoSmithKline/GSK, Janssen-Cilag/J&J, Pfizer, Sanofi, Stemline and Takeda. All other authors declare no conflicts of interest.
